Amyris Finalizes Cannabinoid Development, Licensing and Commercialization Agreement Containing $300 Million of R&D and Milestone Payments and a Long-Term Royalty Stream

Stock Information for Amyris Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Amyris Inc.

AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE
AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9
AMYRIS REPORTS Q1 2023 REVENUE
AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.